KR100503701B1 - 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 - Google Patents
아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 Download PDFInfo
- Publication number
- KR100503701B1 KR100503701B1 KR10-1999-7004446A KR19997004446A KR100503701B1 KR 100503701 B1 KR100503701 B1 KR 100503701B1 KR 19997004446 A KR19997004446 A KR 19997004446A KR 100503701 B1 KR100503701 B1 KR 100503701B1
- Authority
- KR
- South Korea
- Prior art keywords
- adenovirus
- cells
- virus
- cell
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cleaning And De-Greasing Of Metallic Materials By Chemical Methods (AREA)
- Multi-Process Working Machines And Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3132996P | 1996-11-20 | 1996-11-20 | |
| US60/031,329 | 1996-11-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20000057160A KR20000057160A (ko) | 2000-09-15 |
| KR100503701B1 true KR100503701B1 (ko) | 2005-07-26 |
Family
ID=21858843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-1999-7004446A Expired - Lifetime KR100503701B1 (ko) | 1996-11-20 | 1997-11-20 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US6194191B1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP0968284B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4492826B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR100503701B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1244215B (cg-RX-API-DMAC10.html) |
| AT (2) | ATE550429T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU732703B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR9713368A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2272820C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69737107T2 (cg-RX-API-DMAC10.html) |
| ES (2) | ES2278399T3 (cg-RX-API-DMAC10.html) |
| NO (1) | NO992389L (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ335947A (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998022588A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (299)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11511326A (ja) * | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
| US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
| JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| DE69836092T2 (de) * | 1997-10-24 | 2007-05-10 | Invitrogen Corp., Carlsbad | Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen |
| US7705602B2 (en) * | 1997-11-03 | 2010-04-27 | Midtronics, Inc. | Automotive vehicle electrical system diagnostic device |
| US20040204381A1 (en) * | 1997-11-12 | 2004-10-14 | Moskal Joseph R | Detection and treatment of glyco-enzyme-related disease |
| US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| DE69927013T2 (de) * | 1998-04-22 | 2006-06-29 | Genvec, Inc. | Effiziente reinigung von adenovirus |
| US6416992B1 (en) * | 1998-10-13 | 2002-07-09 | Avigen, Inc. | Compositions and methods for producing recombinant adeno-associated virus |
| US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| EP1133316B1 (en) * | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US7148035B1 (en) * | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
| US6210922B1 (en) * | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
| FR2788064B1 (fr) * | 1998-12-31 | 2003-01-31 | Aventis Pharma Sa | Methode de separation de particules virales |
| AU779267B2 (en) | 1998-12-31 | 2005-01-13 | Centelion S.A.S. | Method for separating viral particles |
| CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| US6795585B1 (en) | 1999-07-16 | 2004-09-21 | Eastman Kodak Company | Representing digital images in a plurality of image processing states |
| JP2003518380A (ja) * | 1999-12-29 | 2003-06-10 | ジェンザイム・コーポレイション | 核酸および他の細胞性汚染混入物質からウイルスベクターを分離するための濾過助剤の使用方法 |
| US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
| AU2001257420A1 (en) * | 2000-04-28 | 2001-11-12 | Zengen, Inc. | A gene therapy system and method using alpha-MSH and its derivatives |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US20020064860A1 (en) * | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
| IL157304A0 (en) * | 2001-03-16 | 2004-02-19 | Oncolytics Biotech Inc | Method of extracting virus from cell culture |
| US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
| ATE431396T1 (de) * | 2001-03-27 | 2009-05-15 | Vertex Pharma | Für hcv-infektion geeignete zusammensetzungen und verfahren |
| EP1427835B1 (en) | 2001-08-08 | 2016-01-20 | The Trustees of the University of Pennsylvania | Method for purification of viral vectors having proteins which bind sialic acid |
| US20040253210A1 (en) * | 2001-08-30 | 2004-12-16 | Marjorie Robert-Guroff | Adenovirus type7 vectors |
| WO2003023026A1 (en) * | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003039459A2 (en) * | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
| US7056723B2 (en) * | 2001-12-20 | 2006-06-06 | Bavarian Nordic A/S | Method for the recovery and purification of poxviruses from infected cells |
| KR100451308B1 (ko) * | 2001-12-28 | 2004-10-06 | 선바이오(주) | 단백질 의약품 정제 방법에서의 바이러스 제거 방법 |
| WO2003068804A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Novel insect cell line |
| ES2261921T3 (es) * | 2002-02-20 | 2006-11-16 | MERCK & CO., INC. | Procedimiento para determinar la concentracion de particulas de adenovirus. |
| US20030180936A1 (en) * | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| US20030175688A1 (en) * | 2002-03-15 | 2003-09-18 | Rukmini Pennathur-Das | Method for the purification and production of oncolytic adenoviruses |
| US20030186832A1 (en) * | 2002-03-15 | 2003-10-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Isotropic liquid detergents with improved anti-redeposition |
| JP2005521417A (ja) * | 2002-03-29 | 2005-07-21 | メルク エンド カムパニー インコーポレーテッド | アデノウイルスの大規模産生方法及びアデノウイルス種子ストック |
| DE60327069D1 (de) * | 2002-04-30 | 2009-05-20 | Oncolytics Biotech Inc | Verbesserte reinigungsmethode für viren |
| EP1506287B1 (en) * | 2002-05-14 | 2007-04-25 | Merck & Co., Inc. | Methods of adenovirus purification |
| US20030224354A1 (en) * | 2002-05-30 | 2003-12-04 | Introgen Therapeutics Inc. | Quantifying viral particles with intrinsic fluorescence |
| EP1371723A1 (en) * | 2002-06-12 | 2003-12-17 | Procorde GmbH | Process for preparing an adenovirus-containing preparation |
| US20040219516A1 (en) * | 2002-07-18 | 2004-11-04 | Invitrogen Corporation | Viral vectors containing recombination sites |
| US20040106184A1 (en) * | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| MXPA05003477A (es) * | 2002-10-03 | 2005-07-22 | Targegen Inc | Agentes vasculo-estaticos y metodos de uso de los mismos. |
| US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| EP1558748A4 (en) * | 2002-11-01 | 2008-10-22 | Promega Corp | CELL SYSE COMPOSITIONS, USE METHOD, DEVICE AND KIT |
| AU2003297039B2 (en) * | 2002-12-13 | 2009-03-05 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| AU2003297041B2 (en) * | 2002-12-13 | 2009-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| WO2004060346A2 (en) | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| CA2802143C (en) | 2003-01-14 | 2018-06-19 | Dana-Farber Cancer Institute | Sparc encoding polynucleotide as a cancer therapy sensitizer |
| EP1608762B1 (en) * | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| DE602004008451T2 (de) * | 2003-05-01 | 2008-05-15 | Dsm Ip Assets B.V. | Verfahren zur herstellung von biologischen substanzen durch perfusionskultivierung von suspendierten tierischen zellen |
| US20040229335A1 (en) * | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
| CA2529053A1 (en) * | 2003-06-18 | 2004-12-29 | Onyx Pharmaceuticals, Inc. | Method for purifying virus |
| PT1651666E (pt) * | 2003-07-11 | 2009-08-28 | Alphavax Inc | Vacinas de citomegalovírus à base de alfavírus |
| ES2356154T3 (es) | 2003-07-21 | 2011-04-05 | Transgene S.A. | Citoquinas multifuncionales. |
| DE602004027538D1 (de) * | 2003-12-01 | 2010-07-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
| CA2551026A1 (en) * | 2003-12-23 | 2005-07-14 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
| CN1922308A (zh) * | 2004-02-23 | 2007-02-28 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
| CN100333797C (zh) * | 2005-01-26 | 2007-08-29 | 彭朝晖 | 重组腺病毒p53制品在肿瘤治疗中的新用途 |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| ES2932278T3 (es) * | 2004-06-01 | 2023-01-17 | Genzyme Corp | Composiciones y métodos para prevenir la agregación del vector AAV |
| US20050287616A1 (en) * | 2004-06-29 | 2005-12-29 | Gross Adam F | Method of assaying denaturation of proteins |
| NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
| DE202004014949U1 (de) * | 2004-09-25 | 2004-11-18 | Techno-Grafica Gmbh | Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten |
| DE102004049290A1 (de) * | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Verfahren zur Herstellung von Virusmaterial |
| US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| CN101080488A (zh) * | 2004-11-03 | 2007-11-28 | 因特罗根治疗公司 | 生产和纯化腺病毒载体的新方法 |
| CN100497640C (zh) * | 2004-11-26 | 2009-06-10 | 中国人民解放军军事医学科学院生物工程研究所 | 一种高效生产重组腺病毒载体的方法 |
| US20060166364A1 (en) * | 2004-12-22 | 2006-07-27 | Introgen, Inc. | Use of flexible bag containers for viral production |
| ES2526170T3 (es) * | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
| US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| ATE412737T1 (de) * | 2005-04-11 | 2008-11-15 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
| MX2007013725A (es) * | 2005-05-05 | 2008-04-09 | Sensient Flavors Inc | Produccion de beta-glucanos y mananos. |
| WO2006133411A1 (en) * | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| US20090216452A1 (en) * | 2005-07-05 | 2009-08-27 | Develop Tech Resources | Energy recovery within a fluid distribution network using geographic information |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| DE602007009954D1 (de) * | 2006-03-22 | 2010-12-02 | Viral Logic Systems Technology | Verfahren zur identifizierung von polypeptid-targets |
| WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
| AU2007347716B2 (en) * | 2006-09-15 | 2013-06-20 | Medimmune, Llc | MDCK cell lines supporting viral growth to high titers and bioreactor process using the same |
| CL2008000249A1 (es) | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| US20080299624A1 (en) * | 2007-06-01 | 2008-12-04 | Edward Heslop | Continuous fermentation apparatus and method |
| DK2947149T3 (en) * | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| JP2010539993A (ja) * | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| CA2703263C (en) | 2007-11-01 | 2014-03-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
| US20090253184A1 (en) * | 2008-01-23 | 2009-10-08 | Introgen Therapeutics, Inc. | Compositions and methods related to an adenoviral trans-complementing cell line |
| US10316352B2 (en) * | 2008-05-13 | 2019-06-11 | Gen-Probe Incorporated | Methods of capturing a target nucleic acid for amplification and detection using an inactivatable target capture oligomer |
| WO2009153563A1 (en) * | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| KR20110074563A (ko) | 2008-09-24 | 2011-06-30 | 메디뮨 엘엘씨 | 바이러스의 정제 방법 |
| CN102216450B (zh) * | 2008-09-24 | 2014-05-14 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
| WO2010062757A1 (en) * | 2008-11-03 | 2010-06-03 | Ligocyte Pharmaceuticals, Inc. | Improved methods for isolating enveloped virus-based vlps free of infectious agents |
| EA019928B1 (ru) | 2008-11-03 | 2014-07-30 | Круселл Холланд Б.В. | Способ получения аденовирусных векторов |
| EP2435666A2 (en) * | 2009-05-26 | 2012-04-04 | Leviathan Energy Hydroelectric Ltd. | Hydroelectric in-pipe turbine uses |
| CN103331185A (zh) * | 2009-07-07 | 2013-10-02 | 索尼公司 | 微流体装置 |
| CA2770075C (en) | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition for treating hbv infection |
| WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| MX2012004222A (es) | 2009-10-15 | 2012-06-08 | Crucell Holland Bv | Metodo para purificacion de particulas de adenovirus. |
| MX342641B (es) | 2010-01-05 | 2016-10-07 | Vascular Biogenics Ltd | Metodos para uso de un agente adenoviral anti-angiogenico especifico. |
| MX338931B (es) | 2010-01-05 | 2016-05-06 | Vascular Biogenics Ltd | Composiciones y metodo para tratar gliobastoma (gbm). |
| US20130052165A1 (en) * | 2010-01-12 | 2013-02-28 | Livnat Bangio | Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby |
| PL2536829T3 (pl) | 2010-02-15 | 2016-09-30 | Sposób wytwarzania wektorów adenowirusowych Ad26 | |
| SG184833A1 (en) * | 2010-04-14 | 2012-11-29 | Emd Millipore Corp | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| EP2603234B1 (en) | 2010-08-12 | 2017-06-28 | Yisheng Biopharma Holdings Ltd. | Method for reducing dna impurities in viral compositions |
| CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP2461162A1 (en) | 2010-12-03 | 2012-06-06 | Texcell, . | Method for determining the titre of viruses by using infectious standards |
| CN103476928B (zh) | 2010-12-09 | 2017-03-29 | 巴斯德研究所 | 用于获得高产量重组蛋白表达的基于mgmt的方法 |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
| TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一) |
| WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| WO2013074501A1 (en) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
| KR102044051B1 (ko) | 2012-03-12 | 2019-11-12 | 얀센 백신스 앤드 프리벤션 비.브이. | 터미널 말단이 변경된 재조합 아데노바이러스의 배치 |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| JP5845376B2 (ja) | 2012-03-22 | 2016-01-20 | クルセル ホランド ベー ヴェー | Rsvに対するワクチン |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| JP6334525B2 (ja) * | 2012-07-26 | 2018-05-30 | ブクタリ | 真核細胞に対するウイルスベクター組成物の作用を検出又は測定する方法並びにそれに使用されるバイオマーカー |
| JP6430949B2 (ja) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法 |
| PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
| KR20160003078A (ko) | 2013-05-03 | 2016-01-08 | 허니웰 인터내셔날 인코포레이티드 | 무연 솔더 접속을 위한 리드 프레임 구조체 |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| KR102069561B1 (ko) * | 2013-07-11 | 2020-01-23 | 다카라 바이오 가부시키가이샤 | 외피 비보유 바이러스의 제조 방법 |
| US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| EP3063290B1 (en) * | 2013-10-30 | 2018-11-21 | Merck Patent GmbH | Method for isolating microorganisms from a complex sample |
| JP2017509489A (ja) | 2014-02-20 | 2017-04-06 | ハネウェル・インターナショナル・インコーポレーテッド | 鉛フリーはんだ組成物 |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| CN105316296A (zh) * | 2014-06-13 | 2016-02-10 | 亚宝药业太原制药有限公司 | 一种纯化腺病毒颗粒的方法 |
| WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| GB201417042D0 (en) | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| SG11201704919SA (en) * | 2015-01-13 | 2017-07-28 | Alfa Wassermann Inc | Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) |
| EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| CN107847580B (zh) | 2015-07-07 | 2022-08-12 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| US9663766B2 (en) * | 2015-07-24 | 2017-05-30 | Bio-Rad Laboratories, Inc. | Methods for purifying adenovirus vectors |
| IL258491B2 (en) | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| MX2018012094A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas. |
| DK3722435T3 (da) * | 2016-04-14 | 2025-11-17 | Ferring Ventures Ltd | Fixed-bed-bioreaktor med pumpe/rør-system med konstant flow |
| RS67367B1 (sr) * | 2016-04-14 | 2025-11-28 | Ferring Ventures Ltd | Bioreaktor sa fiksiranim slojem sa pumpom/sistemom creva sa konstantnim protokom |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
| SG11201810078PA (en) | 2016-05-30 | 2018-12-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11001858B2 (en) | 2016-06-20 | 2021-05-11 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| US10053660B2 (en) | 2016-07-12 | 2018-08-21 | California Institute Of Technology | Substrates for high-density cell growth and metabolite exchange |
| US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
| EP3831281B1 (en) | 2016-08-30 | 2026-02-25 | The Regents of The University of California | Devices and systems for biomedical targeting and delivery |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018080573A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
| CN108085301B (zh) * | 2016-11-22 | 2021-10-26 | 贺道耀 | 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒 |
| US10294452B2 (en) | 2016-11-22 | 2019-05-21 | Dao-Yao He | Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells |
| WO2018106888A1 (en) * | 2016-12-08 | 2018-06-14 | Temple University-Of The Commonwealth System Of Higher Education | Small animal models for in vivo testing of polyomavirus therapeutics |
| WO2018148246A1 (en) | 2017-02-07 | 2018-08-16 | Massachusetts Institute Of Technology | Methods and compositions for rna-guided genetic circuits |
| JP7393945B2 (ja) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | 細胞増殖 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| CN107384873A (zh) * | 2017-09-05 | 2017-11-24 | 成都汇宇生物技术有限公司 | 重组腺病毒的纯化方法 |
| AU2018333566A1 (en) | 2017-09-15 | 2020-02-27 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| US11339377B2 (en) * | 2017-11-08 | 2022-05-24 | Bluesky Immunotherapies Gmbh | SO3 chromatography for use in a method for virus purification |
| EP3762500A1 (en) | 2018-03-06 | 2021-01-13 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
| CA3097192A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| US20210207167A1 (en) | 2018-05-16 | 2021-07-08 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
| US20210254103A1 (en) | 2018-07-02 | 2021-08-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| WO2020010110A1 (en) | 2018-07-03 | 2020-01-09 | Unum Therapeutics Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| WO2020037066A1 (en) | 2018-08-14 | 2020-02-20 | Unum Therapeutics Inc. | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| CA3107770C (en) | 2018-08-16 | 2023-09-05 | Emd Millipore Corporation | Closed bioprocessing device |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| EP3833398A4 (en) | 2018-09-21 | 2021-12-22 | University of Connecticut | COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN113166208B (zh) | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| PE20211469A1 (es) | 2018-11-13 | 2021-08-05 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del vrs estabilizadas |
| WO2020123524A1 (en) * | 2018-12-11 | 2020-06-18 | Erbi Biosystems, Inc. | Methods of manufacturing cell based products using small volume perfusion processes |
| CA3125770A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| US11542526B2 (en) | 2019-02-21 | 2023-01-03 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
| CN110093455B (zh) * | 2019-04-27 | 2020-03-17 | 中国医学科学院病原生物学研究所 | 一种呼吸道病毒的检测方法 |
| US20220243225A1 (en) | 2019-04-29 | 2022-08-04 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN112175996A (zh) * | 2019-07-05 | 2021-01-05 | 杭州荣泽生物科技有限公司 | 一种基因治疗载体的制备方法和用途 |
| EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| EP4022070A1 (en) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
| CN114929875A (zh) | 2019-11-15 | 2022-08-19 | 希望之城 | 包含用于腺相关病毒的强化产生的高密度细胞呼吸器的用于产生生物产物的系统、装置和方法 |
| CN110894494B (zh) * | 2019-11-22 | 2022-09-27 | 广西梧州制药(集团)股份有限公司 | 一种大规模高密度悬浮培养293细胞高产腺病毒的方法 |
| WO2021202651A1 (en) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| CA3180222A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| GB202005732D0 (en) | 2020-04-20 | 2020-06-03 | Synpromics Ltd | Regulatory nucleic acid sequences |
| US12630842B2 (en) | 2020-05-13 | 2026-05-19 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
| EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
| CN112226418B (zh) * | 2020-09-25 | 2022-07-08 | 阜外华中心血管病医院 | 重组腺相关病毒纯化方法 |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| CN112293394B (zh) * | 2020-10-30 | 2022-11-25 | 海南德安欣有害生物防治科技有限公司 | 一种捕鼠装置及捕鼠方法 |
| KR20230078805A (ko) | 2020-11-02 | 2023-06-02 | 바이오마린 파머수티컬 인크. | 아데노-연관 바이러스의 농축 공정 |
| GB202019454D0 (en) * | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン |
| US12680110B2 (en) | 2021-08-12 | 2026-07-14 | The University Of Chicago | One-step method for producing adenoviral vectors |
| JP2024534894A (ja) | 2021-09-03 | 2024-09-26 | ビオマリン プハルマセウトイカル インコーポレイテッド | Aavカプシド組成物及び送達方法 |
| EP4396201A1 (en) | 2021-09-03 | 2024-07-10 | BioMarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| US20240384242A1 (en) | 2021-09-03 | 2024-11-21 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| MX2024004009A (es) | 2021-09-27 | 2024-06-19 | Sotio Biotech Inc | Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos. |
| EP4426716A1 (en) | 2021-11-02 | 2024-09-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CA3237201A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| EP4433169A1 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CA3240342A1 (en) | 2021-12-16 | 2023-06-22 | Gopal SAPKOTA | Targeted degradation of alpha-synuclein |
| US20250346920A1 (en) | 2022-01-25 | 2025-11-13 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| JP2025507338A (ja) | 2022-02-08 | 2025-03-18 | ボイジャー セラピューティクス インコーポレイテッド | Aavカプシドバリアント及びその使用 |
| GB202201713D0 (en) | 2022-02-10 | 2022-03-30 | Univ Dundee | An affinity directed phosphatase system for targeted protein dephosphorylation |
| CN115354033A (zh) * | 2022-03-25 | 2022-11-18 | 上海碧博生物医药科技有限公司 | 一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用 |
| EP4532515A1 (en) | 2022-06-02 | 2025-04-09 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| US20260053924A1 (en) | 2022-08-19 | 2026-02-26 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| UY40443A (es) | 2022-09-22 | 2024-02-15 | Biomarin Pharm Inc | Tratamiento de la miocardiopatía con vectores de genoterapia con aav |
| UY40442A (es) | 2022-09-22 | 2024-02-15 | Biomarin Pharm Inc | Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024226790A1 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| JP2026515815A (ja) | 2023-05-03 | 2026-05-19 | ボイジャー セラピューティクス インコーポレイテッド | Cdkl5欠損に関連する障害の治療のための組成物及び方法 |
| WO2024229173A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| IL324036A (en) | 2023-05-03 | 2025-12-01 | Voyager Therapeutics Inc | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2024229164A2 (en) | 2023-05-03 | 2024-11-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| JP2026515970A (ja) | 2023-05-04 | 2026-05-19 | ボイジャー セラピューティクス インコーポレイテッド | Aavカプシドバリアント及びその使用 |
| CN116731981A (zh) * | 2023-06-20 | 2023-09-12 | 天津瑞普生物技术股份有限公司 | 一种鸡新城疫病毒大规模悬浮培养方法 |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025038802A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| WO2025038805A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025038796A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025038430A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| WO2025038795A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025038800A1 (en) | 2023-08-16 | 2025-02-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to frataxin deficiency |
| AR134555A1 (es) | 2023-12-05 | 2026-01-28 | Voyager Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina |
| WO2025122530A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| WO2025122548A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to cdkl5 deficiency |
| WO2025122532A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to ataxin-2 |
| WO2025122536A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025122543A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency |
| WO2025137219A1 (en) | 2023-12-21 | 2025-06-26 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase |
| WO2025147436A1 (en) | 2024-01-03 | 2025-07-10 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
| CN117551624A (zh) * | 2024-01-11 | 2024-02-13 | 深圳源兴基因技术有限公司 | 一种基于无血清悬浮扩增的高效回收腺病毒的方法 |
| WO2025214477A1 (en) | 2024-04-12 | 2025-10-16 | Skyline Therapeutics (Shanghai) Co., Ltd. | Treatment of genetic cardiomyopathies with aav gene therapy vectors |
| WO2026028089A1 (en) | 2024-07-29 | 2026-02-05 | Novartis Ag | Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d) |
| WO2026096600A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering cyclin-dependent kinase-like 5 protein |
| WO2026096611A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering cyclin-dependent kinase-like 5 protein |
| WO2026096603A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering syntaxin-binding protein-1 |
| WO2026096599A1 (en) | 2024-10-30 | 2026-05-07 | Neurocrine Biosciences, Inc. | Compositions and methods for delivering syntaxin-binding protein-1 |
| WO2026102000A1 (en) | 2024-11-06 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency |
| NL2039429B1 (en) | 2024-12-20 | 2026-07-13 | Academisch Ziekenhuis Leiden | Pabpn1 isoforms for use in therapy |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US789244A (en) * | 1902-10-01 | 1905-05-09 | Hans Thormeyer | Steam-turbine. |
| US824544A (en) * | 1905-12-04 | 1906-06-26 | George Hossege | Pipe-hanger. |
| US4222743A (en) * | 1978-07-20 | 1980-09-16 | Wang Wei Kung | Method and apparatus for detecting biological particles by fluorescent stain |
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4539020A (en) * | 1983-07-10 | 1985-09-03 | Kawasaki Steel Corporation | Methods for obtaining high-purity carbon monoxide |
| JPS6147187A (ja) | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 狂犬病ウイルスの精製方法 |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5106841A (en) * | 1986-05-13 | 1992-04-21 | Chai-Tech Corporation | Antiviral compositions and method for their use |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| JPH0761955B2 (ja) | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥a型肝炎ワクチン |
| US5219752A (en) * | 1988-05-25 | 1993-06-15 | Teijin, Limited | Process for continuously culturing adherent animal cells |
| KR910700593A (ko) | 1989-01-16 | 1991-03-15 | 종케 보이젠, 로베르트 아인젤 | 양립성 주파수 분할 다중 텔레비젼 시스템 |
| WO1990013808A1 (de) * | 1989-05-01 | 1990-11-15 | Byk Gulden Lomberg Chem Fab | Reflexionsfluorimeter |
| AU7162991A (en) | 1989-12-12 | 1991-07-18 | Lidak Pharmaceuticals | Free fatty acid determination |
| IT1238231B (it) | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori |
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| IT1248075B (it) | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
| EP0552108B1 (en) * | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| US5323008A (en) * | 1992-03-23 | 1994-06-21 | Diatron Corporation | Fluorometer detection system |
| ES2188593T3 (es) | 1992-03-24 | 2003-07-01 | United Cancer Res Inst | Vacuna que contiene un virus vivo. |
| US5428011A (en) | 1992-06-16 | 1995-06-27 | Procyon Biopharma, Inc. | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma |
| US5733720A (en) * | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
| AU4774093A (en) * | 1992-07-17 | 1994-02-14 | Aprogenex, Inc. | Free radical scavengers useful for reducing autofluorescence in fixed cells |
| CA2144848A1 (en) | 1992-09-18 | 1994-03-31 | H. Michael Shepard | Gene therapy by retroviral vector with tumor suppressive gene |
| US5733721A (en) | 1992-11-20 | 1998-03-31 | The Board Of Regents Of The University Of Oklahoma | Cell analysis method using quantitative fluorescence image analysis |
| WO1994017178A1 (en) | 1993-01-29 | 1994-08-04 | New Brunswick Scientific Co., Inc. | Method and apparatus for anchorage and suspension cell culture |
| US5604096A (en) * | 1993-03-04 | 1997-02-18 | Schaeffer; Warren I. | Fluorometric quantitation of mycoplasmas |
| US5994314A (en) | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| AU6945694A (en) | 1993-05-06 | 1994-12-12 | Dade International Inc. | Human papillomavirus detection assay |
| US5421339A (en) * | 1993-05-12 | 1995-06-06 | Board Of Regents, The University Of Texas System | Diagnosis of dysplasia using laser induced fluoroescence |
| US6686200B1 (en) * | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
| CA2158935A1 (en) | 1993-10-12 | 1995-04-20 | Chiron Viagene, Inc. | Methods for preserving recombinant viruses |
| TW442569B (en) * | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
| EP0738319A4 (en) * | 1994-01-12 | 2000-03-29 | Genetic Therapy Inc | Purification of retroviral vectors |
| HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
| US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
| WO1995025789A1 (en) * | 1994-03-22 | 1995-09-28 | The Immune Response Corporation | Highly efficient production and isolation of viral particles |
| US5521083A (en) * | 1994-05-13 | 1996-05-28 | The Research Foundation Of State University Of New York Et Al. | Large granular lymphocyte leukemia associated virus |
| WO1996009399A2 (en) * | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
| US5552309A (en) | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
| US6348343B2 (en) * | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US5744304A (en) * | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
| US5772888A (en) * | 1995-07-27 | 1998-06-30 | Massachusetts Institute Of Technology | Separation and/or concentration of an analyte from a mixture using a two-phase aqueous micellar system |
| WO1997004803A1 (fr) * | 1995-08-01 | 1997-02-13 | Pasteur Merieux Serums & Vaccins | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
| JPH11511326A (ja) * | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
| CN101028523A (zh) * | 1995-11-30 | 2007-09-05 | 德克萨斯州立大学董事会 | 诊断和治疗肿瘤的方法及组合物 |
| US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
| AR006240A1 (es) * | 1996-03-14 | 1999-08-11 | Fuller H B Licensing Financ | Adhesivo de fusion caliente que comprende interpolimeros, articulo no tejido que lo comprende, procedimiento de polimerizacion para preparlo y caja, envase, bandeja y libro unidos con dicho adhesivo |
| JPH09262099A (ja) * | 1996-03-28 | 1997-10-07 | Aisin Seiki Co Ltd | フルオレセイン誘導体リン酸エステルによる核酸等の検出方法 |
| JP2000514290A (ja) * | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| EP0968284B1 (en) * | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| IL130198A (en) | 1996-12-13 | 2005-09-25 | Schering Corp | Methods for purifying viruses |
| US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US6168944B1 (en) | 1997-01-31 | 2001-01-02 | Schering Corporation | Methods for cultivating cells and propagating viruses |
| DE69837754T2 (de) | 1997-02-18 | 2008-02-07 | Canji, Inc., San Diego | Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| US6130313A (en) | 1997-10-02 | 2000-10-10 | Clontech Laboratories, Inc. | Rapidly degrading GFP-fusion proteins |
| KR100918187B1 (ko) | 1998-02-17 | 2009-09-22 | 쉐링 코포레이션 | 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법 |
| US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
| AU754999B2 (en) | 1998-03-10 | 2002-11-28 | Large Scale Proteomics Corporation | Detection and characterization of microorganisms |
| US6265151B1 (en) * | 1998-03-27 | 2001-07-24 | Seroptix, Inc. | Apparatus and method for infectious disease detection |
| DE69927013T2 (de) * | 1998-04-22 | 2006-06-29 | Genvec, Inc. | Effiziente reinigung von adenovirus |
| US6171790B1 (en) | 1998-05-01 | 2001-01-09 | Incyte Pharmaceuticals, Inc. | Human protease associated proteins |
| AU4188599A (en) | 1998-05-15 | 1999-12-06 | Geron Corporation | Method and apparatus for detecting hazardous agents |
| AU740441B2 (en) | 1998-06-30 | 2001-11-01 | La Mina Ltd | Cytological and histological fixative composition and methods of use |
| AU5429399A (en) | 1998-08-08 | 2000-02-28 | Imperial Cancer Research Technology Limited | Fluorescent assay for biological systems |
| US5965358A (en) | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| AU779267B2 (en) * | 1998-12-31 | 2005-01-13 | Centelion S.A.S. | Method for separating viral particles |
| US6316185B1 (en) * | 1999-09-29 | 2001-11-13 | Mountain View Pharmaceuticals, Inc. | Quantitation of viruses by light scattering |
| JP2002054561A (ja) * | 2000-08-08 | 2002-02-20 | Toyota Industries Corp | 容量可変型圧縮機の制御弁及び容量可変型圧縮機 |
| US6447995B1 (en) * | 2000-10-04 | 2002-09-10 | Genvec, Inc. | Utilizing intrinsic fluorescence to detect adenovirus |
| DE10050114A1 (de) * | 2000-10-09 | 2002-04-25 | Wolf Gmbh Richard | Verwendung einer Gelmasse |
| US20040106184A1 (en) | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| US20040229335A1 (en) * | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
-
1997
- 1997-11-20 EP EP97950677A patent/EP0968284B1/en not_active Expired - Lifetime
- 1997-11-20 ES ES97950677T patent/ES2278399T3/es not_active Expired - Lifetime
- 1997-11-20 EP EP06025694A patent/EP1760151B1/en not_active Expired - Lifetime
- 1997-11-20 US US08/975,519 patent/US6194191B1/en not_active Expired - Lifetime
- 1997-11-20 WO PCT/US1997/021504 patent/WO1998022588A2/en not_active Ceased
- 1997-11-20 CN CN971812543A patent/CN1244215B/zh not_active Expired - Lifetime
- 1997-11-20 EP EP06012869A patent/EP1707631A3/en not_active Withdrawn
- 1997-11-20 BR BR9713368-0A patent/BR9713368A/pt not_active Application Discontinuation
- 1997-11-20 JP JP52396598A patent/JP4492826B2/ja not_active Expired - Lifetime
- 1997-11-20 KR KR10-1999-7004446A patent/KR100503701B1/ko not_active Expired - Lifetime
- 1997-11-20 NZ NZ335947A patent/NZ335947A/xx not_active IP Right Cessation
- 1997-11-20 CA CA2272820A patent/CA2272820C/en not_active Expired - Lifetime
- 1997-11-20 AU AU53617/98A patent/AU732703B2/en not_active Expired
- 1997-11-20 AT AT06025694T patent/ATE550429T1/de active
- 1997-11-20 AT AT97950677T patent/ATE348155T1/de active
- 1997-11-20 ES ES06025694T patent/ES2383640T3/es not_active Expired - Lifetime
- 1997-11-20 DE DE69737107T patent/DE69737107T2/de not_active Expired - Lifetime
-
1999
- 1999-05-19 NO NO992389A patent/NO992389L/no not_active Application Discontinuation
-
2000
- 2000-04-24 US US09/556,570 patent/US6726907B1/en not_active Expired - Lifetime
-
2001
- 2001-12-27 US US10/033,491 patent/US20030008375A1/en not_active Abandoned
- 2001-12-27 US US10/033,571 patent/US7510875B2/en not_active Expired - Fee Related
-
2004
- 2004-07-30 US US10/909,066 patent/US7445930B2/en not_active Expired - Fee Related
-
2006
- 2006-08-23 US US11/508,780 patent/US20070155008A1/en not_active Abandoned
-
2009
- 2009-10-02 US US12/572,943 patent/US20100055763A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20000057160A (ko) | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 | |
| WO1998022588A9 (en) | An improved method for the production and purification of adenoviral vectors | |
| US7125706B2 (en) | Method for the production and purification of adenoviral vectors | |
| US20060166364A1 (en) | Use of flexible bag containers for viral production | |
| KR20060028388A (ko) | 아데노바이러스 벡터의 생산을 위한 방법과 조성물 | |
| US20040106184A1 (en) | Chromatographic methods for adenovirus purification | |
| JP2008518632A (ja) | アデノウイルスベクターの製造および精製のための新規方法 | |
| WO1999027123A2 (en) | Modified sv40 viral vectors | |
| HK1099564A (en) | An improved method for the production and purification of adenoviral vectors | |
| HK1107116B (en) | Adenovirus compositions obtainable by an improved production and purification method | |
| Thwin et al. | c) Patent Application Publication do Pub. No.: US 2002/0177215A1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19990520 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20021119 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041129 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050418 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050718 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20050719 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20080701 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090706 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100706 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110711 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120706 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130705 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130705 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140708 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140708 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150619 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150619 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160616 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160616 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20170616 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170616 Start annual number: 13 End annual number: 13 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20180520 Termination category: Expiration of duration |